Gynecologic and Obstetric Investigation

Original Paper

Endocrinological Meaning of Hyperandrogenism in Patients with Polycystic Ovary

Takahashi K. · Eda Y. · Kusakari M. · Yoshino K. · Kitao M.

Author affiliations

Department of Obstetrics and Gynecology, Shimane Medical University, Japan

Related Articles for ""

Gynecol Obstet Invest 1991;31:46–50

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 23, 1990
Accepted: July 11, 1990
Published online: March 02, 2010
Issue release date: 1991

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: https://www.karger.com/GOI

Abstract

In the light of excessive ovarian androgen hormone production in cases of polycystic ovarian disease (PCO), we have made an endocrinological, symptomatological and morphological study of PCO in women with high serum testosterone levels. The following results were obtained: (1)High serum testosterone levels were found in 18.1 % of the infertile women. (2) Morphologically, 44.4% of these women had PCO (the PCO group), and 55.6% did not have PCO (non-PCO group). (3) No significant differences between these groups were found in mean testosterone, luteinizing hormone (LH), follicle-stimulating hormone (FSH), estrone (El·), 17Β-estradiol (E2) levels, or the E1/E2 ratio, but the LH/FSH ratio was significantly higher in the PCO group. (4) The incidence of menstrual irregularities and hirsutism were significantly higher in the PCO group, but the incidence of obesity did not differ between the groups. (5) No correlation between testosterone and LH or E1 levels was found in the PCO group, but strong positive correlations were found in the non-PCO group. From the above findings it is suggested that in women with high peripheral blood testosterone levels, the presence of morphological abnormalities on the ovaries has effects on gonadotropin production and therefore on the incidence of menstrual irregularities and hirsutism.

© 1991 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Original Paper

Received: January 23, 1990
Accepted: July 11, 1990
Published online: March 02, 2010
Issue release date: 1991

Number of Print Pages: 5
Number of Figures: 0
Number of Tables: 0

ISSN: 0378-7346 (Print)
eISSN: 1423-002X (Online)

For additional information: https://www.karger.com/GOI


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP